Novonesis price target raised to DKK 545 from DKK 520 at JPMorgan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2025
0mins
Should l Buy ?
Source: Business Insider
JPMorgan's Price Target Update: JPMorgan has increased its price target for Novozymes (NVZMY) from DKK 520 to DKK 545 while maintaining an Overweight rating on the shares.
Investment Opportunities: TipRanks offers tools for investors to discover stocks with Strong Buy ratings and optimize their portfolios through a stock screener.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
